A phase II study of Adriamycin in previously untreated squamous cell carcinoma of the head and neck.
Twenty patients with squamous cell carcinoma of the head and neck (SCC H/N) were treated with Adriamycin (doxorubicin) at a dosage of 60 mg/m2 at 3-week intervals. No patient had received surgery, radiation, or chemotherapy before treatment with Adriamycin. Responses were observed in 44% of 18 evaluable tumors. We conclude that Adriamycin is a highly active drug in SCC H/N when no prior treatment has been administered.
D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004317:Doxorubicin / Q000627:therapeutic use*; D004341:Drug Evaluation; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D009367:Neoplasm Staging
D004317:Doxorubicin